Di Wu
Research Subjects
Di Wu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chao Hu
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China
36 shared publications - Dong Wang
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
36 shared publications - Elisabetta Marangoni
Translational Research Department, Institut Curie
36 shared publications - Frank Wu
TransThera Sciences (Nanjing), Inc., Nanjing, China
36 shared publications - Guoyu Li
Department of Medicinal Chemistry, Pharmacology, Project Management, Drug Metabolism and Pharmacokinetics, TransThera Sciences (Nanjing), Inc., Nanjing, Jiangsu, P.R. China
36 shared publications - Laura Sourd
Institut Curie 2 Laboratory of Preclinical Investigation, Translational Research Department Paris, France
36 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure FS6 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib effectively blocks JAK/STAT3/IDO signaling pathway.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure FS6 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib effectively blocks JAK/STAT3/IDO signaling pathway.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure FS4 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib indirectly blocks EGFR signaling pathway without affecting PTPN12.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure FS4 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib indirectly blocks EGFR signaling pathway without affecting PTPN12.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
This includes the supplementary methods and supplementary table captions.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
This includes the supplementary methods and supplementary table captions.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure FS7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib blunts EMT in TNBC.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure FS7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib blunts EMT in TNBC.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure FS2 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
As shown in Figure 2, Image J was applied for semi-quantification for each protein level as indicated.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure FS2 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
As shown in Figure 2, Image J was applied for semi-quantification for each protein level as indicated.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure FS8 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib is well tolerated through the in vivo studies and body weight curves are shown.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure FS8 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib is well tolerated through the in vivo studies and body weight curves are shown.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure FS9 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib possesses robust immunomodulatory activity.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure FS9 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib possesses robust immunomodulatory activity.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Supplementary Tables S1-7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Supplementary Tables S1-7 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure FS1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib highly inhibits TNBC cell by a panel of specific mechanisms.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure FS1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib highly inhibits TNBC cell by a panel of specific mechanisms.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure FS3 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib effectively blocks Aurora kinase signaling pathway.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure FS3 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Tinengotinib effectively blocks Aurora kinase signaling pathway.